Navigation Links
VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
Date:4/14/2008

-New Instrument Generates Real-Time In Vivo Data via Quantitative

Tomography-

WOBURN, Mass., April 14 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging, today announced the commercial launch of its FMT 2500 small animal imaging system. The FMT 2500 is based on VisEn's proprietary Fluorescence Molecular Tomography (FMT(TM)) technology platform, and combined with VisEn's portfolio of fluorescence in vivo imaging agents, enables researchers to rapidly and easily generate quantitative data on key disease biologies and therapeutic response profiles in animal research models. The FMT 2500 launch was announced at the 2008 annual meeting of the American Association for Cancer Research. VisEn has already placed several beta units with leading academic and pharmaceutical customers in the United States and in Europe, and expects to begin commercial deliveries this quarter.

"The key feature of the FMT 2500 is the FMT(TM) technology platform that enables researchers to generate Quantitative Tomographic data in vivo, unlike any other fluorescence imaging technology platform or system on the market," said Kirtland Poss, President and Chief Executive Officer of VisEn Medical. "Further, due to some breakthrough advances in the system design and FMT software algorithms, this new system generates unmatched data performance, without the need for any index matching fluid. With these performance advances and additional product design improvements, this new system brings the well-validated power of the FMT technology platform to the broader research markets."

The FMT technology platform enables Quantitative Tomographic in vivo data by using three key steps: data generation, data normalization, and fluorescence tomographic reconstruction. The system offers multiplexed imaging capabilities so users can measure, monitor and compare multiple in vivo biologic targets, pathways or processes simultaneously using different fluorescence agents. Using a proprietary FMT 2500 animal imaging cassette that is compatible with multiple imaging modalities, researchers can also co-register FMT data with imaging readouts from other modalities, including CT, MR and PET. FMT image and data outputs can be exported into industry and clinical standard formats, and are DICOM compatible. VisEn also offers a range of fluorescence imaging agents for measuring key biologic targets, pathways and processes in animal models of inflammation, cancer, and skeletal, cardiovascular or pulmonary disease.

About VisEn Medical, Inc.

VisEn Medical, Inc. was founded in 2000 based on fluorescence in vivo imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn develops and commercializes the industry's highest performing fluorescence in vivo imaging technology platforms, from research through medicine. The Company also works directly with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are targeted to their specific research areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures, Merck Capital Ventures and The Bollard Group. For further information please visit http://www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... 2016 , ... HealthSmart Holdings, Inc. announced today the launch ... and information to lower the costs, and increase the impact of their healthcare ... healthcare benefits by as much as 22%:, + Price and quality transparency, ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... , ... February 06, 2016 , ... With the ... add warm color grades to their footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. By manipulating each pixel, LUT's can ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016 Wegener Polyangiitis - Pipeline ... Direct,s, ,Wegener Polyangiitis - Pipeline Review, H2 2015, ... pipeline. This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
(Date:2/4/2016)... 2016 Frontier Pharma: Chronic Obstructive Pulmonary ... Chronic Obstructive Pulmonary Disease (COPD) ... of the airways and lungs. Persistent breathing difficulties ... disease one of the leading causes of morbidity ... world. COPD is linked to cumulative exposure to ...
(Date:2/4/2016)... -- In response to the opioid abuse epidemic, today Dr. ... Products and Tobacco, along with other FDA leaders, called for ... opioid medications. The plan will focus on policies aimed at ... to effective relief. --> ... risk-benefit paradigm for opioids and ensure that the agency considers ...
Breaking Medicine Technology: